相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion
Jeffrey J. Liu et al.
NEUROPSYCHOPHARMACOLOGY (2019)
A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Kendall L. Mores et al.
FRONTIERS IN PHARMACOLOGY (2019)
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses
Amelia D. Dunn et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice
Yan Zhou et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2019)
Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice
Amelia D. Dunn et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
In vivo brain GPCR signaling elucidated by phosphoproteomics
Jeffrey J. Liu et al.
SCIENCE (2018)
Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch® capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus
Hideki Kozono et al.
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE (2018)
Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor
Selena S. Schattauer et al.
CELLULAR SIGNALLING (2017)
Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?
A. Albert-Vartanian et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2016)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria
Tarsis F. Brust et al.
SCIENCE SIGNALING (2016)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria
Tarsis F. Brust et al.
SCIENCE SIGNALING (2016)
The G Protein-Biased kappa-Opioid Receptor Agonist RB-64 Is Analgesic with a Unique Spectrum of Activities In Vivo
Kate L. White et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Synthesis and Pharmacological Evaluation of 5-Pyrrolidinylquinoxalines as a Novel Class of Peripherally Restricted κ-Opioid Receptor Agonists
Christian Bourgeois et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives
Toru Nemoto et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects
Katherine A. MacLean et al.
PSYCHOPHARMACOLOGY (2013)
Efficacy and Safety of a Novel K-Agonist for Managing Intractable Pruritus in Dialysis Patients
Hiroo Kumagai et al.
AMERICAN JOURNAL OF NEPHROLOGY (2012)
Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology
Hiroshi Nagase et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning
JP McLaughlin et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Comparison of pharmacological activities of three distinct kappa ligands (salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo
Y Wang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Effect of the endogenous κ opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice
Y Zhang et al.
PSYCHOPHARMACOLOGY (2004)
Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys
SS Negus
PSYCHOPHARMACOLOGY (2004)
Pharmacotherapy of addictions
MJ Kreek et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Effects of a newly synthesized κ-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats
T Mori et al.
PSYCHOPHARMACOLOGY (2002)
Antipruritic activity of the κ-opioid receptor agonist, TRK-820
Y Togashi et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Conditioned place preference: what does it add to our preclinical understanding of drug reward?
MT Bardo et al.
PSYCHOPHARMACOLOGY (2000)
分享论文
